Novel methods are reported for evaluating and utilizing single chain fragment variable (scFv) antibodies derived from yeast-display libraries. Yeast-display was used to select scFv specific to invariant surface glycoproteins (ISG) of Trypanosoma brucei. A limiting step in the isolation of scFv from nonimmune libraries is the conversion of highly active yeast-displayed scFv into soluble antibodies that can be used in standard immunoassays. Challenges include limited solubility or activity following secretion and purification of scFv. For this reason, few scFv derived from yeast-display platforms have moved into development and implementation as diagnostic reagents. To address this problem, assays were developed that employ both yeastdisplayed and secreted scFv as analytical reagents. The first is a competitive inhibition flow cytometry (CIFC) assay that detects secreted scFv by virtue of their ability to competitively inhibit the binding of biotinylated antigen to yeast-displayed scFv. The second is an epitope binning assay that uses secreted scFv to identify additional yeast-displayed scFv that bind nonoverlapping or noncompeting epitopes on an antigen. The epitope binning assay was used not only to identify sandwich assay pairs with yeast-displayed scFv, but also to identify active soluble scFv present in low concentration in a crude expression extract. Finally, a CIFC assay was developed that bypasses entirely the need for soluble scFv expression, by using yeastdisplayed scFv to detect unlabeled antigen in samples. These methods will facilitate the continued development and practical implementation of scFv derived from yeast-display libraries.
Introduction
Sleeping sickness, also called Human African Trypanosomiasis (HAT), is caused by the protozoan parasites Trypanosoma brucei gambiense and T. brucei rhodesiense. Following insect-borne transmission, systemic disease is characterized by parasites spreading through the lymph, bloodstream, and other organs (Checchi et al. 2008; Fevre et al. 2008) . Eventually, the parasite infects the central nervous system resulting in severe neurological symptoms. Left untreated, the infection is nearly always fatal (Burri and Brun 2009; Checchi et al. 2008) .
Diagnosis of HAT is problematic and is typically based on ruling out of malaria, microscopic visualization of parasites, and, for T. brucei gambiense, a positive card agglutination test (Simarro et al. 2008) . Patients who receive a correct diagnosis can be effectively treated, however drugs for late-stage disease are highly toxic. To reduce life-long disabilities and the need for toxic late-stage treatments, diagnostic tests are needed to detect the infection early.
Ideally, new tests should detect parasites or parasite components, because tests for immune responses cannot discriminate between active and past infections (Buscher and Lejon 2004) .
The surfaces of bloodstream form T. brucei trypomastigotes are covered with highly immunogenic variable surface glycoproteins (VSG) (Kennedy 2008; Stockdale et al. 2008; Van Meirvenne et al. 1977) . Frequent variation of the antigenic type of VSG complicates detection of parasites by immunoassays (Buscher and Lejon 2004) . Within the VSG layer are invariant surface glycoproteins (ISG) that do not antigenically shift and are present in the bloodstream form of all T. brucei isolates examined (Burgess and Jerrells 1985; Tran et al. 2008; Tran et al. 2006; Ziegelbauer and Overath 1992; Ziegelbauer et al. 1995) . For this reason, ISG have been targeted as markers for diagnosis of HAT (Tran et al. 2008; Ziegelbauer and Overath 1992) .
A c c e p ted P r e p r i nt
The present study targeted three ISG, namely ISG64, ISG65, and ISG75, with the goal of generating panels of scFv that could be further used to develop an immunoassay for parasite detection. IgG or IgM antibodies specific to ISG have not been useful for detection of T. brucei cells in patient samples, in part because of their hypothetical inability to penetrate the densely packed VSG shield on living trypanosomes. To this end, efforts are aimed at generating single chain fragment variable (scFv) antibodies specific to ISG64, ISG65, and ISG75. Because scFv antibodies are much smaller in size (~32-38 kDa) than IgG or IgM antibodies, they are hypothesized to be capable of penetrating the VSG layer and binding to ISG.
ScFv antibodies are fragments derived from immunoglobulin (commonly IgG or IgM) antibodies containing a single variable heavy (V H ) domain and a single variable light or kappa (V L or V k ) domain connected via a flexible amino acid linker. A library of 10 9 nonimmune human scFv antibodies displayed on the surface of the yeast Saccharomyces cerevisiae has been used as a source of antigen-specific scFv (Feldhaus et al. 2003) . For use in functional assays, scFv isolated from the library can be cloned into expression vectors for production in heterologous hosts such as E. coli or yeast and the soluble scFv purified for use in biological assays (Boder and Wittrup 2000; Miller et al. 2005; Siegel et al. 2004) .
A limitation of yeast-displayed scFv libraries has been the difficulty of generating soluble scFv antibodies as translational reagents. To help address this problem, researchers have compared protein secretion systems (Miller et al. 2005; Shusta et al. 1998) to improve the yield and activity of secreted scFv. For example, thioredoxin fusions with scFv have been shown to enhance solubility and folding in the cytoplasm of E. coli (Jurado et al. 2006; Jurado et al. 2002) .
More recently, scFv were purified and used as detection reagents by microarray (Seurynck-
Servoss et al. 2008).
A c c e p ted P r e p r i nt 
Materials and Methods.

Materials
Recombinant ISG75 from T. brucei gambiense LiTat1.3 was cloned and expressed as described previously (Tran et al. 2008; Tran et al. 2006 Selections from the yeast-displayed human nonimmune scFv library Selections were performed as described previously (Chao et al. 2006; Feldhaus and Siegel 2004; Feldhaus et al. 2003; Siegel et al. 2004 ). The first two rounds of magnetic sorting were conducted with a cocktail containing all three biotinylated ISG antigens at 100 nanomolar (nM) each. For round 3, the round 2 output was incubated with each biotinylated antigen separately at 100 nM. Antigen-binding yeast cells were detected by incubating with streptavidinphycoerythrin (SA-PE), followed by flow cytometric analysis and sorting of the top 1% of PE positive yeast. The sorted yeast cells, constituting the round 3 outputs, were grown on synthetic dextrose casamino acid (SDCAA) minus-His/Ura/Trp agar plates supplemented with penicillin and streptomycin (both at 50 g mL -1 ). For ISG75, aliquots of yeast cells were incubated separately with 1 nM, 10 nM, and 100 nM biotinylated antigen, sorted, and grown on plates as described above.
ScFv production and purification
Plasmids were isolated from 21 antigen-selected, FACS-sorted yeast clones and scFv inserts were PCR-amplified from 10-fold diluted plasmid template as described (Feldhaus et al. 2003) using Phusion Taq DNA Polymerase. Each scFv amplicon was ligated into four vectors: pET28a, pET27b, pET32b (EMD Biosciences, Darmstadt, Germany), and pET102d (Invitrogen, Carlsbad, CA). Single transformant colonies were selected and inserts confirmed for size and directionality by PCR and sequencing. The plasmids were transformed into E. coli expression A c c e p ted P r e p r i nt hosts Rosetta BL21 ( DE3) (for scFv in pET27b and pET28a) or Origami BL21 ( DE3) (for scFv in pET32b and pET102d).
ScFv expressed from pET27b were purified as described (Miller et al. 2005) . Expressed scFv from pET28a, pET32b, and pET102d were purified using the MagnaHis method as follows: E.
coli transformants were picked into 2 mL deep well plates and grown in 2 mL LB supplemented with 50 g mL -1 ampicillin. 
Activity of secreted scFv by Biacore
Biacore assays were performed with the purified TrxA-scFv using a Biacore 3000 instrument, and data were fit using BIAEvaluation 3.1 software (GE Healthcare). Approximately 12,000 RU of mouse anti-TrxA MAb was covalently linked to a Biacore CM5 chip using EDC/NHS amine coupling chemistry. TrxA-scFv were diluted 1/10 in Hepes Buffered Saline containing 0.005%
A c c e p ted P r e p r i nt until 400-1000 RU of scFv was captured. Cognate unlabeled ISG at a concentration of 500 nM was then injected for three minutes at a flow rate of 40 L min -1 .
Epitope binning assay for identifying ELISA-compatible scFv pairs
Yeast-displayed scFv were incubated with 100 L of 200 nM unlabeled ISG75 for one hour. To calculate percent inhibition, the equation [% inhibition = 100-(y-mean fluorescence at X nM inhibitor/ y-mean fluorescence at 0 nM inhibitor)*100] was applied. Data were plotted, and y-mean fluorescence calculated using the FlowJo flow cytometry software analysis program (Tree Star, Inc., Ashland, OR). To confirm specificity of the assay, triplicate measurements were made with the same antigen concentration series as above, except that the antigen was an irrelevant protein, PhoS1 from Mycobacterium tuberculosis (Braibant et al. 1996) . Robustness was assessed by conducting replicate reactions with varying numbers of W75C6 yeast cells or with varying concentrations of biotinylated ISG75.
Results
Selection of yeast clones with antigen-specific binding activity began with two rounds of magnetic particle enrichment followed by 1 to 2 rounds of flow cytometric cell sorting.
Incubations of the round 3 output with antigen showed significant reactivity to ISG75 (~5% ISG75-positive at 100 nM antigen), slightly less reactivity to ISG65 (6.0% at 200 nM), and slight reactivity to ISG64 (0.12% at 100 nM are 59% conserved and 37% identical (data not shown). ISG75 exhibited lower conservation (30% and 32%, respectively) and identity (17% and 16%, respectively) with ISG64 and ISG65
(not shown). It is possible that some of the cross reactivity exhibited between ISG64 and ISG65 clones may be due to epitopes common to both antigens.
ScFv genes from all 21 ISG-binding yeast clones were sub-cloned into four E. coli expression vectors: pET28a, pET27b, pET32b, and pET102d. The plasmid pET27b adds a N-terminal PelB leader sequence which localizes scFv to the periplasm, thereby facilitating purification (Miller et al. 2005) . The plasmids pET32b and pET102d encode an N-terminal thioredoxin fusion (TrxA)
to the expressed proteins. The TrxA fusion enhances expression and cytoplasmic folding of scFv (Jurado et al. 2006; Jurado et al. 2002; Seurynck-Servoss et al. 2008 ). The vector pET102d was chosen, in addition to pET32b, to take advantage of additional cloning and expression features.
Small scale expression cultures were performed followed by MagneHis purification. All clones yielded proteins of the predicted molecular weight as determined by SDS-PAGE (data not shown). Many of the scFv formed inclusion bodies in the cytoplasm of E. coli, however only the soluble fractions were tested for activity. SDS-PAGE and anti-6X-His Western analysis showed that many scFv formed multimers, most typically dimers.
The TrxA-scFv were tested by Biacore following capture to an immobilized anti-TrxA MAb. A competitive inhibition flow cytometry antibody (CIFC-Ab) assay, which is diagrammed in Figure 1 (far left), was developed to assess the activities in solution of scFv expressed in E. coli.
The assay was performed by incubating purified soluble TrxA-scFv with 20 nM of biotinylated cognate antigen and allowing them to bind to equilibrium. The scFv-antigen mix was then added to a suspension of yeast cells displaying the same scFv on their surfaces. If the soluble scFv is active, then it is expected to bind and occupy the epitope and thereby prevent the yeast-displayed scFv from binding. Flow cytometry was used to quantify this competitive activity as reduced PE-fluorescence relative to a baseline control in which biotinylated antigen was incubated with cognate yeast cells without pre-incubation with purified scFv. Analysis of all 21 scFv in the CIFC-Ab assay identified 6 scFv that exhibited competitive inhibition above a threshold value of 3-fold, and 15 that did not (Table 1) . Although the threshold value was chosen arbitrarily, the quantitative results facilitate the prioritization of relatively active scFv for future development.
A c c e p ted P r e p r i nt
To test the specificity of the CIFC assay, a negative control was performed in which two soluble scFv, W65B3 and W64C4, were incubated with the non-cognate biotinylated antigen ISG75 in solution. Although both of these scFv exhibited CIFC activity when incubated with their cognate antigens, they failed to inhibit binding of the non-cognate antigen ISG75 to W75D4 yeast (Table 1) . This result was expected if the inhibition observed with ISG75-specific Abs was antigen specific. Positive controls used W75D4 scFv purified using large scale HPLC methods and confirmed to be active by Biacore analysis. These scFv exhibited somewhat greater overall activity versus the same scFv in the crude MagneHis purifications (results of two separate HPLC purifications are shown in Table 1 ).
In order to further characterize scFv activities without requiring ELISA or Biacore analyses, a flow cytometry-based epitope binning assay was developed to rapidly identify scFv pairs that bind to non-overlapping epitopes on an antigen. Figure 2A shows an epitope binning assay in which ISG75 was incubated with three yeastdisplayed ISG75-specific clones and then detected by using soluble TrxA-scFv W75D4.
Positive results were observed when scFv W75C2 or scFv W75C6 was used as soluble detection probe. Therefore, either of these scFv can be paired with W75D4 in sandwich assays. In contrast, ISG75 bound to yeast W75D4 was not detected using TrxA-scFv W75D4 as a detection probe, as expected given that this antigen typically exists primarily in a monomeric state (Tran et al. 2008) . To further confirm that the assay reflects specific interactions, it was repeated using yeast-displayed W75C6 and soluble W75D4, except that three non-cognate antigens, each at 200 nM, were used ( Figure 2B ). The results demonstrated specificity to the cognate antigen, ISG75. 
The experiment in Figure 3 used biotinylated ISG75 at a concentration of 100 nM and 100,000 yeast cells per incubation. Because competitive inhibition assays can be sensitive to the stoichiometry of antibody probe concentrations, the robustness of the assay was evaluated by varying the number of yeast cells used per antigen incubation. The CIFC-Ag assay exhibited similar performance using 50,000, 100,000, 200,000, or 400,000 yeast cells per incubation ( Figure 4A ). All four curves exhibited lower limits of detection (LLD) of at least 2 nM.
Similarly, variations in the concentration of biotinylated ISG75 (2 nM, 20 nM, or 100 nM) did not strongly perturb the assay ( Figure 4B ).
Discussion
Trypanosoma brucei has a surface layer of variable surface glycoproteins (VSG) that mask invariant proteins, including ISG, from detection reagents and from host immune responses.
Structural and density studies have found the VSG proteins to be densely packed (Homans et al. 1989 ). Researchers are working to develop lower molecular weight affinity reagents that will have a better chance of penetrating the VSG shield and binding conserved VSG or ISG epitopes.
Examples include nanobodies (Baral et al. 2006; Saerens et al. 2008; Stijlemans et al. 2004 )and RNA aptamers Homann et al. 2006; Menger et al. 2006) . In the present study, we generated a panel of scFv antibodies and specific assays to assess scFv activity and identify candidate scFv that can be further developed for diagnostic assays.
Selections were performed on a yeast-displayed human nonimmune scFv library to isolate scFv clones that bound specifically to ISG64, ISG65, and ISG75. ISG75 generated the most significant binding response and greatest number of antigen-specific scFv clones. Consistent with the partial homology between ISG64 and ISG65, several clones bound both antigens.
A c c e p ted P r e p r i nt A limitation of synthetic scFv antibody libraries has been the generation of translational reagents, specifically scFv that can be isolated in soluble, secreted, and active form for direct application in diagnostic assays. Genes encoding 21 scFv were subcloned into four E. coli expression vectors. E. coli was chosen as the expression system over Saccharomyces cerevisiae
and Pichia pastoris expression platforms because E. coli was shown in numerous comparisons to be superior for scFv expression (Jurado et al. 2006; Miller et al. 2005; Seurynck-Servoss et al. 2008 ). Despite these advantages of the E. coli system, many scFv predominately form inclusion bodies. There are several protocols for solubilization and refolding of scFv antibodies, however these are laborious and a unique protocol must be developed for each scFv. The CIFC-Ab assay may offer a more rapid and economical strategy, in which large numbers of candidate scFv are screened for activity without the requirement for refolding.
Crude scFv purifications were tested for antigen binding activity in solution by Biacore analysis. This approach identified only 1 active scFv out of 21 scFv tested. Not knowing whether this low frequency of activity was a characteristic of ISG selections or a technical limitation of scFv analysis in the absence of pre-existing ISG-specific antibodies, novel assays were developed which do not require pre-existing antibodies to detect soluble scFv activity. One of these was CIFC-Ab, a competitive inhibition assay that measures activity of scFv in crude protein purifications. CIFC-Ab may be able to detect scFv with low percent activity in solutions containing excess inactive scFv due to misfolding or denaturation. In contrast, Biacore analysis,
A c c e p ted P r e p r i nt Of 21 scFv examined by CIFC-Ab, 6 exhibited activity that exceeded the threshold value of 3
fold inhibition relative to the no scFv control. Several other scFv exhibited activity ranging from 1.5 to 2.8 fold inhibition. These may have had activity but they were not prioritized for further development.
A second assay, termed epitope binning, was developed to identify compatible scFv sandwich assay pairs and to further prioritize scFv candidate antibodies. In this assay, a panel of yeast, each displaying a scFv to a given antigen, were bound to unlabeled cognate antigen. The bound antigen was then detected using a soluble purified scFv specific to the cognate antigen. Binding of the soluble scFv was detected by a fluorophore or antibody specific to an epitope tag that exists only on the soluble scFv, and not on the displayed scFv. The antigen was detected only if the soluble scFv binds to a non-competing and non-overlapping epitope from the yeast-displayed
scFv. An advantage of the epitope binning assay is that only one soluble antibody is required to perform the assay while the remaining scFv can be yeast-displayed. By identifying compatible scFv pairs for sandwich assays and other diagnostic test formats, the epitope binning assay can A c c e p ted P r e p r i nt further prioritize scFv for cloning, secretion, and purification. The method can also serve as an alternative to CIFC-Ab, ELISA, and Biacore as a means to identify novel scFv activities in solution.
For some applications, it would be useful to eliminate altogether the need for the extracellular expression and purification of active scFv. This is possible if scFv-displaying yeast cells are used directly as detection reagents. For example, intact yeast have been used to immunoprecipitate antigens from solution for subsequent detection by mass spectrometry (Cho et al. 2009 ). The CIFC-Ag assay reported here follows a similar strategy but eliminates the need for separate detection methods such as mass spectrometry. Using the CIFC-Ag assay, yeast cells which displayed a scFv with an estimated affinity of 52 nM detected unlabeled antigen in solution at concentrations down to 2 nM. This level of sensitivity is comparable to that which might be expected of an ELISA that utilizes an antibody with similar affinity. The CIFC-Ag assay was robust, in that probe concentrations could be varied without strongly affecting assay performance.
All three flow cytometry-based methods described in this report were easy to set up and inexpensive to perform. They required no pre-existing soluble antibodies and little in the way of optimization. They were fast, requiring less than two hours to complete. These methods may facilitate the development and utilization of scFv antibodies derived from yeast display and other in vitro selection methods.
A c c e p ted P r e p r i nt A c c e p ted P r e p r i nt and then incubated with excess biotinylated ISG75 followed by SA-PE. To evaluate specificity, the assay was also conducted using a nonspecific potential inhibitor, PhoS1. Each line represents the mean and standard deviation of three independent trials. All of these assays were performed with the ISG75-specific yeast clone W75C6.
